Design Therapeutics (DSGN) Research & Development (2020 - 2026)
Design Therapeutics (DSGN) posted quarterly Research & Development of $16.4 million for Q2 2026, up 4.13% year-over-year from $15.7 million in Q2 2025, and up 13.97% on a QoQ basis from $14.4 million in Q1 2026.
Design Therapeutics (DSGN) Research & Development (2020 - 2026) Analysis & Trends
Design Therapeutics has reported Research & Development for 7 years, with the latest figure at $16.4 million in Q2 2026.
- Research & Development for Q2 2026 came in at $16.4 million, up 4.13% year-over-year; the trailing twelve-month figure through Jun 2026 was -$248000.0 (down 100.45% YoY), and the FY2025 annual result was $100000.0, down 99.77% from the prior year.
- Research & Development improved to $16.4 million in Q2 2026, from $14.4 million in the prior quarter.
- Over five years, Research & Development peaked at $17.1 million in Q2 2023 and troughed at -$45.6 million in Q4 2025.
- A 5-year average of $10.0 million and a median of $13.8 million in 2022 frame the typical range for Research & Development.
- The widest annual swing landed in 2022, when Research & Development jumped 126.04%; it then sank 475.13% in 2025.
- A 5-year view of Research & Development shows it stood at $14.3 million in 2022, then retreated by 22.75% to $11.0 million in 2023, then advanced by 10.4% to $12.2 million in 2024, then sank by 475.13% to -$45.6 million in 2025, then jumped by 135.94% to $16.4 million in 2026.
- Per Business Quant data, the three most recent Research & Development figures were $16.4 million in Q2 2026, $14.4 million in Q1 2026, and -$45.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Design Therapeutics | 928.06 Mn | 720.67 Mn | - | 16.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.39 Mn |
| Mar 31, 2026 | 14.38 Mn |
| Dec 31, 2025 | -45.60 Mn |
| Sep 30, 2025 | 14.59 Mn |
| Jun 30, 2025 | 15.74 Mn |
| Mar 31, 2025 | 15.38 Mn |
| Dec 31, 2024 | 12.16 Mn |
| Sep 30, 2024 | 11.88 Mn |
| Jun 30, 2024 | 10.52 Mn |
| Mar 31, 2024 | 9.80 Mn |
| Dec 31, 2023 | 11.01 Mn |
| Sep 30, 2023 | 13.26 Mn |
| Jun 30, 2023 | 17.06 Mn |
| Mar 31, 2023 | 15.73 Mn |
| Dec 31, 2022 | 14.26 Mn |
| Sep 30, 2022 | 14.30 Mn |
| Jun 30, 2022 | 11.30 Mn |
| Mar 31, 2022 | 8.76 Mn |
| Dec 31, 2021 | 7.34 Mn |
| Sep 30, 2021 | 8.54 Mn |